Novartis hopes new data will open a $1 billion market opportunity for its radioligand therapy, Lutathera, as a first-line treatment.
On Thursday, Bicycle Therapeutics announced the appointments of Lisa Mahnke as senior vice president and head of clinical and Terrence West as vice president and head of program management to help expand and advance its clinical pipeline.
Novartis may be struggling a bit in the U.S. with cancer drug launches, but it has a new market it can now explore: Saudi Arabia.
Did Novartis game Europe`s orphan program to overprice Lutathera?